The China in vitro diagnostics (IVD) market was valued at USD 5.5 billion in 2023 and is projected to grow steadily through 2030. This expansion is supported by rising prevalence of chronic and infectious diseases including diabetes, cancer, tuberculosis, and other communicable conditions, as well as increasing healthcare investment and demand for early diagnostic testing. Testing technologies, especially those enabling rapid and accurate detection, have become more essential following the COVID-19 pandemic, which significantly accelerated the adoption of diagnostic solutions for disease surveillance and population health management. Government healthcare initiatives focusing on preventive care and diagnostic accessibility continue to stimulate demand, particularly among the aging population. Innovation and commercialization efforts by international and domestic companies are also contributing to broader market penetration and technological advancement. The market’s structural characteristics demonstrate a high degree of technological innovation, driven by investments in research and expansion of diagnostic platforms and services.

Key Market Trends & Insights

  • By Product, the reagents segment dominated the market, accounting for a revenue share of 66% in 2023.
  • By Technology, the immunoassay segment led the market with a revenue share of 32% in 2023.
  • By Application, the infectious diseases segment held the largest share, contributing 36% of total revenue in 2023.
  • By End Use, the hospitals segment dominated the market with a revenue share of 43% in 2023.
  • By Test Location, the point-of-care segment accounted for a revenue share of 21.76% in 2023.

Market Size & Forecast

  • Market Size (2023): USD 5.5 billion
  • Projected Market Size (2030): USD 8.4 billion
  • CAGR (2024–2030): 6.4%

The reagents segment commanded a dominant share of the product market in 2023 with 66% of total revenue, reflecting its integral role in diagnostic testing. Reagents, including kits used for a wide range of assays, continue to attract extensive research and development activity. Enhancements such as faster-acting cancer detection kits and globally certified diagnostic assays are key drivers of adoption and revenue growth. Concurrently, instrument sales are anticipated to grow rapidly over the forecast period as technological improvements introduce portable, automated, and user-friendly systems that facilitate enhanced laboratory and point-of-care diagnostics. For example, integrated sequencing platforms and automated PCR systems are gaining traction for genetic analysis and infectious disease testing due to their precision and throughput.

From a technology perspective, the immunoassay segment led in 2023 with approximately 32% revenue share. This category includes tests that identify the presence or interaction of antibodies and antigens, which are widely used for detecting infectious organisms such as bacteria, viruses, and fungal agents. The development of novel immunological diagnostic tools continues as companies seek to improve accuracy and expand clinical applicability. The coagulation segment is poised for the fastest growth, propelled by increased incidence of cardiovascular and blood-related disorders. Advancements in handheld coagulation analyzers and point-of-care clotting assessment tools are enhancing diagnostic workflows across clinical settings.

In terms of applications, tests for infectious diseases accounted for around 36% of market revenue in 2023. The heightened focus on infectious disease diagnostics, which was magnified by COVID-19 demands, continues through ongoing product development and collaborative efforts to improve access to advanced testing. Meanwhile, drug testing is recognized as the fastest-growing application segment, driven by the expanding use of toxicology screening and substance abuse testing in medical, occupational, and sports environments. The development of point-of-care drug testing platforms supports rapid clinical decision-making in emergency and outpatient settings.

Order a free sample PDF of the China In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insight

The competitive landscape of the China IVD sector is characterized by both multinational and domestic players deploying strategic collaborations, product innovations, acquisitions, and geographic expansion to increase market share. Leading entities focus on broadening their diagnostic portfolios to include advanced reagents, automated instruments, and integrated digital diagnostic solutions that meet diverse clinical needs. Although launching new assays and securing regulatory approvals remain challenging, industry players continue to invest in production and service infrastructure within China to capitalize on expanding demand. Strategic investments such as manufacturing expansions support capacity for high-demand technologies like liquid chromatography and mass spectrometry systems.

The market also reflects dynamic competition, with companies navigating pricing pressures, regulatory frameworks, and investment in next-generation diagnostics. Collaboration agreements aimed at integrating novel sequencing and molecular technologies further highlight the industry’s movement toward more comprehensive and precise diagnostic tools. Expansion initiatives are particularly focused on enhancing access to quality diagnostics within tier-2 and rural regions, aligning with public health goals to reduce gaps in early disease detection and management.

Key Companies List

The following are among the principal participants in the China IVD market:

  • Abbott
  • bioMérieux SA
  • Mindray Medical International Limited
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Shanghai Kehua Bio-Engineering Co. Ltd.
  • Thermo Fisher Scientific Inc.
  • Sysmex Corporation
  • Maccura Biotechnology
  • Siemens Healthcare GmbH Grand View Research

Conclusion

Overall, the China in vitro diagnostics market is progressing through sustained growth underpinned by rising disease burden, healthcare modernization, supportive policies, and technological innovation. Reagents and instruments remain focal product segments, while immunoassay and coagulation technologies drive differentiated value propositions. Infectious disease and drug testing applications reflect diverse diagnostics demand, and both institutional and decentralized care settings are influencing broader adoption. Competitive dynamics and strategic investments by key market players are expected to further catalyze market expansion through 2030, reinforcing China’s role as a pivotal and fast-growing segment within the global IVD industry.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.